Edition:
United States

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

54.44USD
22 May 2017
Change (% chg)

-- (--)
Prev Close
$54.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
551,345
52-wk High
$74.90
52-wk Low
$11.57

CLVS.OQ

Chart for CLVS.OQ

About

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $2,437.42
Shares Outstanding(Mil.): 44.77
Dividend: --
Yield (%): --

Financials

  CLVS.OQ Industry Sector
P/E (TTM): -- 142.93 17.37
EPS (TTM): -8.23 -- --
ROI: -61.85 2.34 -5.89
ROE: -159.36 0.22 -5.30

BRIEF-Clovis Oncology Q1 loss per share $1.33

* Clovis Oncology announces first quarter 2017 operating results

May 03 2017

BRIEF-Myriad Genetics, Clovis Oncology sign agreement for use of FDA-approved BRACAnalysis CDx test

* Myriad Genetics and Clovis oncology sign agreement for use of FDA-approved BRACAnalysis CDX® test to identify patients with Germline BRCA mutations for Rubraca® (rucaparib) treatment

Apr 27 2017

BRIEF-Clovis Oncology Q4 loss per share $1.83

* Q4 earnings per share view $-1.64 -- Thomson Reuters I/B/E/S

Feb 22 2017

BRIEF-Clovis Oncology and Strata Oncology announce collaboration in prostate cancer development program

* Clovis Oncology and Strata Oncology announce collaboration to accelerate enrollment in rucaparib prostate cancer development program

Feb 01 2017

BRIEF-Millennium Management reports 5.1 pct passive stake in Clovis Oncology

* Millennium Management Llc reports 5.1 percent passive stake in Clovis Oncology Inc as of Jan 6, 2017 - Sec filing Source: (http://bit.ly/2iHJ0N2) Further company coverage:

Jan 11 2017

Clovis's ovarian cancer drug wins accelerated FDA approval

The U.S. Food and Drug Administration granted accelerated approval to Clovis Oncology Inc's ovarian cancer drug in patients with a specific gene mutation whose disease had advanced despite two or more rounds of chemotherapy.

Dec 19 2016

More From Around the Web

Competitors

Earnings vs. Estimates